Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | LONP1 | P36776 | 7/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.42 |
| ▸ | PSMB11 | A5LHX3 | 6/20 | 0.42 |
| ▸ | PSMA7 | O14818 | 6/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 6/20 | 0.42 |
| ▸ | PSMA1 | P25786 | 6/20 | 0.42 |
| ▸ | PSMA2 | P25787 | 6/20 | 0.42 |
| ▸ | PSMA3 | P25788 | 6/20 | 0.42 |
| ▸ | PSMA4 | P25789 | 6/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 6/20 | 0.42 |
| ▸ | PSMB9 | P28065 | 6/20 | 0.42 |
| ▸ | PSMA5 | P28066 | 6/20 | 0.42 |
| ▸ | PSMB4 | P28070 | 6/20 | 0.42 |
| ▸ | PSMB6 | P28072 | 6/20 | 0.42 |
| ▸ | PSMB10 | P40306 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833929 | 0.93 | MMP12 (0.44) | MMP12CTSLCTSBMMP9MMP8 | |
| SCHEMBL5833801 | 0.92 | MMP9 (0.42) | MMP12MMP9MMP8LONP1PSMB5 | |
| SCHEMBL5833288 | 0.91 | MMP9 (0.44) | MMP12CTSLCTSBMMP9MMP8 | |
| SCHEMBL5833133 | 0.90 | GPR132 (0.49) | CTSLCTSBMMP9MMP8LONP1 | |
| SCHEMBL5833182 | 0.88 | ACACB (0.49) | CTSLCTSB | |
| SCHEMBL5832975 | 0.86 | MAOB (0.46) | CTSLCTSBLONP1PSMB5PSMB11 | |
| SCHEMBL5833262 | 0.85 | ACACB (0.48) | CTSLCTSB | |
| SCHEMBL5833113 | 0.85 | REN (0.42) | PSMB5 | |
| SCHEMBL5833850 | 0.84 | CTSL (0.49) | MMP12CTSLCTSBMMP9MMP8 | |
| SCHEMBL5832749 | 0.83 | GPR132 (0.51) | MMP9MMP8LONP1PSMB5PSMB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | claimed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | claimed |
| US-6989448-B2 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN | 2006-01-24 | — | — | US | disclosed |
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6469038-B1 | CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY | WARNER-LAMBERT COMPANY | 2002-10-22 | — | — | US | disclosed |
| US-6166052-A | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | WARNER-LAMBERT COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060419-A1 | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers | CACNA1C, CACNA1I, CACNA1S | MMP12 1662/4885CTSL 861/4885CTSB 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.